

Exhibit 356

JIMMY C. LARAMORE V. UNITED STATES OF AMERICA
EXPERT REPORT OF JOHN SFAKIANOS, M.D.
MATERIALS CONSIDERED

1. All materials identified and cited in my Report of February 7, 2025
2. Plaintiffs' Master Complaint dated October 6, 2023, In re Camp Lejeune Water Litigation, No. 7:23-cv-897 (EDNC)
3. Short Form Complaint – Jimmy C. Laramore
4. Discovery Pool Profile Form – Jimmy C. Laramore
5. Deposition and exhibits, Jimmy C. Laramore
6. Declaration of Jimmy C. Laramore dated January 30, 2025
7. Supplemental Response to Plaintiff's First Set of interrogatories for Jimmy C. Laramore dated August 28, 2024
8. Deposition and exhibits, Dr. David G. Alonzo
9. Deposition and exhibits, Dr. Warren T. Hitt
10. Deposition and exhibits, Dr. Henry E. Ruiz
11. Deposition and exhibits, Dr. David L. Spencer, Jr.
12. Medical record summary – Jimmy C. Laramore
13. General causation expert report of Dr. Steven Bird dated December 9, 2024
14. General causation expert report of Dr. Benjamin Hatten dated December 9, 2024
15. General causation expert report of Dr. Kathleen Gilbert dated December 9, 2024
16. General causation expert report of Dr. Laura Plunkett dated December 9, 2024
17. General causation expert report of Dr. Stephen Culp dated December 9, 2024
18. Expert Report of Morris L. Maslia, PE, DWRE, DEE, Fellow EWRI, including Appendices H1, J, and K

19. Supplemental Report on Camp Lejeune Water Contamination and EPA Ban of TCE and PCE by Dr. Steven Bird dated February 4, 2025.
20. Exposure charts of Dr. Kelly Reynolds, MSPH, PhD: Laramore Model Cumulative Exposure and Date Summary.
21. Supplemental Expert report of Dr. Steven Bird regarding Jimmy C. Laramore dated February 7, 2025
22. Supplemental report of Dr. Benjamin Hatten regarding Jimmy C. Laramore dated February 7, 2025
23. 40 CFR Part 751, Federal Register Vol. 89, No. 242 – 102568 (December 17, 2024) and Vol. 89, No. 243 -103560 (December 18, 2024) (EPA 2024)
24. Aschengrau A, Ozonoff D, Paulu C, et al. Cancer risk and tetrachloroethylene-contaminated drinking water in Massachusetts. *Arch Environ Health*. 1993;48(5):284-292. doi:10.1080/00039896.1993.9936715
25. ATSDR. Analyses of Groundwater Flow, Contaminant Fate and Transport, and Distribution of Drinking Water at Tarawa Terrace and Vicinity, U.S. Marine Corps Base Camp Lejeune, North Carolina: Historical Reconstruction and Present-Day Conditions—Chapter A: Summary of Findings, 2007
26. ATSDR. *Analyses and Historical Reconstruction of Groundwater Flow, Contaminant Fate and Transport, and Distribution of Drinking Water Within the Service Areas of the Hadnot Point and Holcomb Boulevard Water Treatment Plants and Vicinities, U.S. Marine Corps Base Camp Lejeune, North Carolina*. Chapter A: Summary and Findings, 2013.
27. ATSDR Assessment of the Evidence for the Drinking Water Contaminants at Camp Lejeune and Specific Cancers and Other Diseases, 2017
28. ATSDR Public Health Assessment, 2017
29. Boice JD Jr, Marano DE, Cohen SS, Mumma MT, Blot WJ, Brill AB, Fryzek JP, Henderson BE, McLaughlin JK. Mortality among Rocketdyne workers who tested rocket engines, 1948-1999. *J Occup Environ Med*. 2006 Oct;48(10):1070-92.
30. Bove FJ, Greek A, Gatiba R, et al. Cancer Incidence among Marines and Navy Personnel and Civilian Workers Exposed to Industrial Solvents in Drinking Water at US Marine Corps Base Camp Lejeune: A Cohort Study. *Environ Health Perspect*.

2024;132(10):107008. doi:10.1289/EHP14966Bove FJ, Ruckart PZ, Maslia M, Larson TC. Evaluation of mortality among marines and navy personnel exposed to contaminated drinking water at USMC base Camp Lejeune: a retrospective cohort study. *Environmental Health*. 2014;13(1):10. doi:10.1186/1476-069X-13-10

31. Bove FJ, Ruckart PZ, Maslia M, Larson TC. Mortality study of civilian employees exposed to contaminated drinking water at USMC Base Camp Lejeune: a retrospective cohort study. *Environmental Health*. 2014;13(1):68. doi:10.1186/1476-069X-13-68

32. Bove FJ, Ruckart PZ, Maslia M, Larson TC. Evaluation of mortality among marines and navy personnel exposed to contaminated drinking water at USMC base Camp Lejeune: a retrospective cohort study. *Environ Health*. 2014 Feb 19;13(1):10.

33. Bove FJ, Ruckart PZ, Maslia M, Larson TC. Mortality study of civilian employees exposed to contaminated drinking water at USMC Base Camp Lejeune: a retrospective cohort study. *Environ Health*. 2014 Aug 13;13:68.

34. Guha et al., Carcinogenicity of trichloroethylene, tetrachloroethylene, some other chlorinated solvents, and their metabolites. *The Lancet Oncology*. 2012. Vol. 13, 1192-1193

35. Hadkhale K, Martinsen JI, Weiderpass E, et al. Occupational exposure to solvents and bladder cancer: A population-based case control study in Nordic countries. *Int J Cancer*. 2017;140(8):1736-1746. doi:10.1002/ijc.30593

36. Hansen J, Sallmén M, Seldén AI, Anttila A, Pukkala E, Andersson K, Bryngelsson IL, Raaschou-Nielsen O, Olsen JH, McLaughlin JK. Risk of cancer among workers exposed to trichloroethylene: analysis of three Nordic cohort studies. *J Natl Cancer Inst*. 2013 Jun 19;105(12):869-77

37. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Some Drinking-water Disinfectants and Contaminants, including Arsenic. Lyon (FR): International Agency for Research on Cancer; 2004. (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, No. 84.) Monographs on Chloramine, Chloral and Chloral Hydrate, Dichloroacetic Acid, Trichloroacetic Acid and 3-Chloro-4-(Dichloromethyl)-5-Hydroxy-2(5H)-Furanone.

38. Raaschou-Nielsen O, Hansen J, McLaughlin JK, et al. Cancer risk among workers at Danish companies using trichloroethylene: a cohort study. *Am J Epidemiol*. 2003;158(12):1182-1192. doi:10.1093/aje/kwg282
39. Vlaanderen J, Straif K, Ruder A, Blair A, Hansen J, Lynge E, Charbotel B, Loomis D, Kauppinen T, Kyyronen P, Pukkala E, Weiderpass E, Guha N. Tetrachloroethylene exposure and bladder cancer risk: a metaanalysis of dry-cleaning-worker studies. *Environ Health Perspect*. 2014 Jul;122(7):661-6.
40. Zhao Y, Krishnadasan A, Kennedy N, Morgenstern H, Ritz B. Estimated effects of solvents and mineral oils on cancer incidence and mortality in a cohort of aerospace workers. *Am J Ind Med*. 2005 Oct;48(4):249-58.
41. 00897_PLG_0000082087
42. 00897_PLG_0000083518
43. 00897_PLG_0000088731
44. 000594_LARAMORE_VBA-0000000001-66
45. 000594_LARAMORE_VBA-0000000067-125
46. 000594_LARAMORE_VBA-0000000126-273
47. 000594_LARAMORE_VBA-0000001056-71
48. 000594_LARAMORE_VBA-0000001223-1410
49. 000594_LARAMORE_VBA-0000001579-87
50. 000594_LARAMORE_VBA-0000001590-97
51. 000594_LARAMORE_VBA-0000001598-1606
52. 000594_LARAMORE_VBA-0000001851-75
53. 000594_LARAMORE_VBA-0000001933-59
54. 000594_LARAMORE_VBA-0000001960-88
55. 000594_LARAMORE_VBA-0000002057-85
56. 000594_LARAMORE_VBA-0000002107-10
57. 000594_LARAMORE_VBA-0000002157-313
58. 000594_LARAMORE_VBA-0000002314-79
59. 000594_LARAMORE_VBA-0000002380-2543
60. 000594_LARAMORE_VBA-0000002609-11
61. 000594_LARAMORE_VBA-0000002690-834

62. 000594_LARAMORE_VBA-0000002837-70
63. 000594_LARAMORE_VBA-0000002871-99
64. 000594_LARAMORE_VBA-0000002900-12
65. 000594_LARAMORE_VBA-0000002913
66. 000594_LARAMORE_VBA-0000002914-3076
67. 000594_LARAMORE_VBA-0000003084-93
68. 000594_LARAMORE_VBA-0000003528-45
69. 000594_LARAMORE_VBA-0000003675-81
70. 000594_LARAMORE_VBA-0000003684-91
71. 000594_LARAMORE_VBA-0000003702-19
72. 000594_LARAMORE_VBA-0000003732-40
73. 000594_LARAMORE_VBA-0000003741-51
74. 000594_LARAMORE_VBA-0000004035-45
75. 000594_LARAMORE_VBA-0000004052-66
76. 000594_LARAMORE_VBA-0000004067-84
77. 000594_LARAMORE_VBA-0000004114-35
78. 000594_LARAMORE_VBA-0000004184-98
79. 000594_LARAMORE_VBA-0000004199-4238
80. 000594_LARAMORE_VBA-0000004239-47
81. 000594_LARAMORE_VBA-0000004248-63
82. 000594_LARAMORE_VBA-0000004264-80
83. 000594_LARAMORE_VBA-0000004281-96
84. 000594_LARAMORE_VBA-0000004297-334
85. 000594_LARAMORE_VBA-0000004335-99
86. 000594_LARAMORE_VBA-0000004419-35
87. 000594_LARAMORE_VBA-0000004447-78
88. 000594_LARAMORE_VBA-0000004479-534
89. 000594_LARAMORE_VHA-0000000001
90. 000594_LARAMORE_VHA-0000000002
91. 000594_LARAMORE_VHA-0000000008-430
92. 000594_LARAMORE_VHA-0000000437-440

93. 000594_LARAMORE_VHA-0000000441-447
94. 000594_LARAMORE_VHA-0000000448-456
95. 000594_LARAMORE_VHA-0000000457-991
96. 000594_LARAMORE_VHA-0000000992-996
97. 000594_LARAMORE_VHA-0000000997-1012
98. 000594_LARAMORE_VHA-0000001022-48
99. 000594_LARAMORE_VHA-0000001049-54
100. 000594_LARAMORE_VHA-0000001055-1676
101. 000594_LARAMORE_VHA-0000001677-1896
102. 000594_LARAMORE_VHA-0000001898-914
103. 00594_LARAMORE_0000000004-232
104. 00594_LARAMORE_0000000233-48
105. 00594_LARAMORE_0000000249-399
106. 00594_LARAMORE_0000000400-587
107. 00594_LARAMORE_0000000588-631
108. 00594_LARAMORE_0000000632-679
109. 00594_LARAMORE_0000000680-727
110. 00594_LARAMORE_0000000728-69
111. 00594_LARAMORE_0000000770-94
112. 00594_LARAMORE_0000000795-821
113. 00594_LARAMORE_0000000822-850
114. 00594_LARAMORE_0000000851-4
115. 00594_LARAMORE_0000000856-1012
116. 00594_LARAMORE_0000001013-78
117. 00594_LARAMORE_0000001079-242
118. 00594_LARAMORE_0000001247-52
119. 00594_LARAMORE_0000001257-401
120. 00594_LARAMORE_0000001402-35
121. 00594_LARAMORE_0000001436-64
122. 00594_LARAMORE_0000001465-77
123. 00594_LARAMORE_0000001478

124. 00594_LARAMORE_0000001479-641
125. 00594_LARAMORE_0000001642-51
126. 00594_LARAMORE_0000001652-756
127. 00594_LARAMORE_0000001757-2019
128. 00594_LARAMORE_0000002020-37
129. 00594_LARAMORE_0000002038-94
130. 00594_LARAMORE_0000002095-101
131. 00594_LARAMORE_0000002102-09
132. 00594_LARAMORE_0000002110-27
133. 00594_LARAMORE_0000002148-58
134. 00594_LARAMORE_0000002159-73
135. 00594_LARAMORE_0000002174-91
136. 00594_LARAMORE_0000002192-213
137. 00594_LARAMORE_0000002216-30
138. 00594_LARAMORE_0000002231-70
139. 00594_LARAMORE_0000002271-79
140. 00594_LARAMORE_0000002280-95
141. 00594_LARAMORE_0000002296-312
142. 00594_LARAMORE_0000002313-28
143. 00594_LARAMORE_0000002329-66
144. 00594_LARAMORE_0000002367-431
145. 00594_LARAMORE_0000002432-49
146. 00594_LARAMORE_0000002450-66
147. 00594_LARAMORE_0000002467-98
148. 00594_LARAMORE_0000002499-554
149. 00594_LARAMORE_0000002555-608
150. 00594_LARAMORE_0000002609-45
151. 00594_LARAMORE_0000002646-58
152. 00594_LARAMORE_0000004251-308
153. 00594_LARAMORE_0000004309-765
154. 00594_LARAMORE_0000004771-896

155. 00594_LARAMORE_0000004918-5091
156. 00594_LARAMORE_0000005092-6258
157. 00594_LARAMORE_0000006259-6610
158. 00594_LARAMORE_0000006611-30
159. 00594_LARAMORE_AUI_0000000001-78
160. 00594_LARAMORE_DHRH_0000000001-2
161. 00594_LARAMORE_DHRH_0000000003-139
162. 00594_LARAMORE_UA_0000000001-140
163. 00594_LARAMORE_UA_0000000141-240
164. 00594_LARAMORE_VHA_0000001917-2082
165. 00594_LARAMORE_VHA_0000002083-2206
166. 00594_LARAMORE_VHA_0000002207-83
167. 00594_LARAMORE_VHA_0000002284-449
168. 00594_LARAMORE_VHA_0000002450-3449
169. 00594_LARAMORE_VHA_0000003450-3595
170. 00594_LARAMORE_VHA_0000003596-607
171. 00594_LARAMORE_VHA_0000003608
172. 00594_LARAMORE_VHA_0000003609-4628
173. 00594_LARAMORE_VHA_0000004631-803
174. 00594_LARAMORE_VHA_0000004807-10
175. 00594_LARAMORE_VHA_0000004812-23

Dr. Sfakianos reserves the right: to review and consider additional facts, data and publications; to consider the report of any other witness in this action; the right to supplement this Materials Considered List; and the right to consider the report of any other witness in this action.